An overview of the effects of anti-IgE therapies

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1691-1699

  Yalcin, Arzu Didem ^a  

^a GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Anti IgE; Asthma; Chronic urticaria; Inflammatory proteins; Omalizumab

Indexed keywords

ALLERGEN; ANTITHROMBIN III; APC PROTEIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CD200 ANTIGEN; CERULOPLASMIN; CORTICOSTEROID; CYTOKINE; D DIMER; EOSINOPHIL CATIONIC PROTEIN; HEPARIN; HOMOCYSTEINE; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LEUKOCYTE ELASTASE; NITRIC OXIDE; OMALIZUMAB; OREXIN 2 RECEPTOR; PEROXIDASE; PROTEIN C; PROTEIN S; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG; VITAMIN D; WARFARIN; ANTI-IGE ANTIBODIES; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; ATOPIC DERMATITIS; BLOOD CLOTTING; CHRONIC URTICARIA; EOSINOPHILIC GASTROENTERITIS; FOOD ALLERGY; HUMAN; HYPER IGE SYNDROME; MASTOCYTOSIS; NOSE POLYP; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; SAMTERS SYNDROME; SEVERE PERSISTENT ASTHMA; ANIMAL; DESENSITIZATION; DRUG EFFECTS; ECONOMICS; METABOLISM;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COAGULATION; DESENSITIZATION, IMMUNOLOGIC; HUMANS; OXIDATIVE STRESS; RECEPTORS, IGE;

EID: 84908132216     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.890137     Document Type: Article

References (97)

1. Babu KS, Polosa R, Morjaria JB: Anti-IgE emerging opportunities for Omalizumab. Expert Opin Biol Ther, 2013; 13(5): 765-77
2. Kaplan A, Ledford D, Ashby M et al: Omalizumab in chronic idiopathic/spontaneous urticaria patients symptomatic despite standard combination therapy. J Allergy Clin Immunol, 2013; 132: 101-9
3. Yalcin AD, Bisgin A, Gorczynski RM: IL-8, IL10, TGF-β and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment. Mediators Inflamm, 2012; 2012: 720976
4. Yalcin AD, Bisgin A: A case of heterozygous factor V leiden and prothrombin G20210A carrier and irregular emphysema/ severe allergic asthma of succesful Anti-IgE therapy without any arteriothrombotic event and increases of serum protein C and S levels. European Journal of Allergy and Clinical Immunology, 2013; 68: 24
5. Kim B, Eggel A, Tarchevskaya SS et al: Accelerated disassembly of IgEreceptor complexes by a disruptive macromolecular inhibitor. Nature, 2012; 491(7425): 613-17
6. Chang TW: Developing antibodies for targeting immunoglobulin and membrane bound immunoglobulin E. Allergy Asthma Proc, 2006; 27: S7-14
7. Chang TW, Shiung YY: Anti IgE as a mast cell stabilizing therapeutic agent. J. Allergy Clin Immunol, 2006; 117: 1203-12
8. Chang TW: The pharmacological basis of anti-IgE therapy. Nat Biotechnol, 2000; 18: 157-62
9. Adcock LM, Caramori G, Chung KF: New targets for drug development in asthma. Lancet, 2008: 372(9643): 1073-87
10. Heaney GL, Robinson DS: Severe asthma treatment: need for characterising patients. Lancet, 2005; 365(9463): 974-76
11. Yalcin AD, Cilli A, Bisgin A et al: Omalizumab is effective in treating severe asthma in patients with severe cadiovascular complications and its effects on sCD200, d-dimer, CXCL8 and IL-1β levels. Expert Opin Biol Ther, 2013; 13(9): 1335-41
12. Yalcin AD, Celik B, Gumuslu S: D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment. Expert Opin Biol Ther, 2014; 14(3): 283-86
13. Yalcin AD, Bisgin A, Cetinkaya R et al: Clinical Course and Side Effects of Omalizumab in Patients with Severe Persistent Asthma. Clin Lab, 2013; 59: 71-77
14. Yalcin AD, Ucar S, Gumuslu S et al: Effects of Omalizumab on Eosinophil Cationic Peptid, 25-Hydroxyvitamin-D, IL-1β, and sCD200 in a cases of Samter’s syndrome: 36 Months follow-up. Immunopharmacol Immunotoxicol, 2013; 35(4): 524-27
15. Yalcin AD, Bisgin A: Anti-IgE Therapy in Severe Allergic Conditions. J Allergy Ther, 2012; 3: 120
16. Yalcin AD, Bisgin A, Kargi A et al: Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treatment. Med Sci Monit, 2012; 18(3): PI11-15
17. Yalcin AD, Bisgin A: The Relation of sTRAIL Levels and Quality of Life In Omalizumab Using Severe Persistent Allergic Asthma Patients. Med Sci Monit, 2012; 18(8): LE9-10. (WISC 2012: WAO Outstanding Abstract Award)
18. Yalcin AD, Gumuslu S, Parlak GE et al: Soluble TRAIL as a marker of efficacy of allergen-spesific immunotherapy in patients with allergic rhinoconjunctivitis. Med Sci Monit, 2012; 18(10): CR617-21
19. Yalcin AD, Ozdemir L, Polat HH: Evaluation Of Socio- Demographic characteristics of Patients Receiving Spesific Immunotherapy In Antalya. (029: oral presentation, APSR, 3-6 November 2011, China), Respirology, 2011; 16(Suppl.): 191
20. Yalcin AD, Bisgin A, Akman A et al: A rare Side effect of immunotherapy: Jessner-Kanoff lymphocytic infiltrate. Journal of Investigational Allergology & Clinical Immunology, 2012; 22(4): 308-9
21. Yalcin AD, Bisgin A, Polat HH: The incidence of the epidemiological markers of allergy in adults. J Clin Anal Med, 2014; 5(2): 138-43
22. Yalcin AD, Basaran S: The effects of climate and aero allergens changes in allergic rhinoconjunctvitis and allergic asthma patients in mediterranean region between 2011 and 2012. Med Sci Monit, 2013; 19: 710-11
23. Holgate S, Smith N, Massanari M et al: Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy, 2009; 64(12): 1728-36
24. Eckman JA, Sterba PM, Kelly D et al: Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol, 2010; 125(4): 889-95
25. Kuehr J, Brauburger J, Zielen S et al: Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol, 2002; 109(2): 274-80
26. Rolinck-Werninghaus C, Hamelmann E, Keil T et al: The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy, 2004; 59(9): 973-79
27. Kopp MV, Hamelmann E, Zielen S et al: Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy, 2009; 39(2): 271-79
28. Massanari M, Nelson H, Casale T et al: Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol, 2010; 125(2): 383-89
29. Casale TB, Busse WW, Kline JN et al: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol, 2006; 117(1): 134-40
30. Kontou-Fili K: High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy, 2008; 63(3): 376-78
31. Schulze J, Rose M, Zielen S: Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy, 2007; 62(8): 963-64
32. Yalcin AD, Kose S, Gorczynski RM: Clinical Experience in Allergic Asthma Patients: Omalizumab with Immunotherapy. World Allergy Organ J, 2012; 5(Suppl.2): S105
33. Yalcin AD, Gumuslu S, Parlak GE et al: Systemic Levels Of Ceruloplasmin Oxidase Activity In Allergic Asthma And Allergic Rhinitis. Immunopharmacol Immunotoxicol, 2012; 34(6): 1047-53
34. Barber EF, Cousins RJ: Interleukin-1 - stimulated induction of ceruloplasmin synthesis in normal and copper-deficient rats. J Nutr, 1988; 118: 375-81
35. Kennedy T, Ghio AJ, Reed W et al: Copper-dependent inflammation and nuclear factor-kappa B activation by particulate air pollution. Am J Respir Cell Mol Biol, 1998; 19: 366-78
36. Yalcin AD, Gorczynski RM, Parlak GE et al: Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab, 2012; 58(1-2): 89-96
37. Yalcin AD, Genc GE, Bisgin A et al: Evaluation of Homocysteine, 25(OH) Vitamin D, Pro-inflammatory IL-1β and Immune Modulator OX-2 Levels in Moderate Allergic Asthma Patients: Association with Biological Treatment & Disease Activity. J Clin Pharm Therapy, ID: 2366 [in press]
38. Dawson H, Collins G, Pyle R et al: The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev, 2004; 125: 107-10
39. Schroecksnadel K, Frick B, Wirleitner B et al: Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol, 2003; 134: 53-56
40. Durand P, Lussier-Cacan S, Blache D: Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J, 1997; 11: 1157-68
41. Bellamy MF, McDowell IF, Ramsey MW et al: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults. Circulation, 1998; 98: 1848-52
42. Anderson OS, Sant KE, Dolinoy DC: Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J Nutr Biochem, 2012; 23: 853-59
43. Finkelstein JD, Martin JJ: Homocysteine. Int J Biochem Cell Biol 2000; 32: 385-89
44. Korn S, Hübner M, Jung M et al: Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res, 2013; 14(1): 25
45. Chambers ES, Nanzer AM, Richards DF et al: Serum 25-dihydroxyvitamin D levels correlate with CD4(+)Foxp3(+) T-cell numbers in moderate/severe asthma. J Allergy Clin Immunol, 2012; 130(2): 542-44
46. Kriebitzsch C, Verlinden L, Eelen G et al: 1,25-dihydroxyvitamin D3 influences cellular homocysteine levels in murine preosteoblastic MC3T3-E1 cells by direct regulation of cystathionine β-synthase. J Bone Miner Res, 2011; 26(12): 2991-3000
47. Gorczynski RM: CD200: CD200R-Mediated Regulation of Immunity. ISRN Immunology, 2012, doi: 10.5402/2012/682168 [in press]
48. Yalcin AD, Genc GE, Celik B et al: Anti-IgE monoclonal antibody (omalizumab) is effective in treating Bullous Pemphigoid and effects on soluble CD200. Clin Lab, 2014; 60(3): 523-24
49. Yalcin AD, Karakas AA, Soykam G et al: A Case of Toxic Epidermal Necrolysis with Diverse Etiologies: Successful Treat-ment with Intravenous Immunoglobulin and Pulse Prednisolone and Effects on sTRAIL and sCD200 Levels. Clin Lab, 2013; 59(5-6): 681-85
50. Akman-Karakas A, Yalcin AD, Koc S et al: There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders. Med Sci Monit, 2013; 19: 888-91
51. Akman-Karakas A, Yalcin AD, Koc S et al: The serum soluble CD200 level was higher than for healthy individuals in patients with Bullous Pemphigoid during the active phase of the disease. Clin Lab, 2014 [in press]
52. Boer JD, Majoor CJ, Veer CV et al: Asthma and coagulation. Blood, 2012; 119: 3236-44
53. Danese S, Vetrano S, Zhang L et al: The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood, 2010; 115(6): 1121-30
54. Hataji O, Taguchi O, Gabazza EC et al: Activation of protein C pathway in the airways. Lung, 2002; 180(1): 47-59
55. Criado PR, Antinori LC, Maruta CW et al: Evaluation of D-dimer serum levels among patients with chronic urticaria, psoriasis and urticarial vasculitis. An Bras Dermatol, 2013; 88(3): 355-60
56. Triwongwaranat D, Kulthanan K, Chularojanamontri L, Pinkaew S: Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. Asia Pac Allergy, 2013; 3: 100-5
57. Ritis K, Doumas M, Mastellos D et al: A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol, 2006; 177(7): 4794-802
58. Niven AS, Argyros G: Alternate treatments in asthma. Chest, 2003; 123(4): 1254-65
59. Heimall J, Freeman A, Holland SM: Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol, 2010; 38(1): 32-38
60. Mogensen TH: STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties. JAKSTAT, 2013; 2(2): e23435
61. Freeman AF, Holland SM: The hyper-IgE syndromes. Immunol Allergy Clin North Am, 2008; 28(2): 277-91
62. Freeman AF, Holland SM: Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res, 2009; 65(5 Pt 2): 32R-37R
63. Chularojanamontri L, Wimoolchart S, Tuchinda P et al: Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol, 2009; 27(4): 233-36
64. Bard S, Paravisini A, Avilés-Izquierdo JA et al: Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol, 2008; 144(12): 1662-63
65. Belloni B, Ziai M, Lim A et al: Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol, 2007; 120: 1223-25
66. Simoniuk U, McManus C, Kiire C: Eosinophilic gastroenteritis a diagnostic enigma. BMJ Case Rep, 2012; 2012: pii: bcr1220115436
67. Alfadda AA, Storr MA, Shaffer EA: Eosinophilic colitis: epidemiology, clinical features, and current management. Therap Adv Gastroenterol, 2011; 4(5): 301-9
68. Lucendo AJ, Arias A: Eosinophilic gastroenteritis: an update. Expert Rev Gastroenterol Hepatol, 2012; 6(5): 591-601
69. Alfadda AA, Storr MA, Shaffer EA: Eosinophilic colitis: an update on pathophysiology and treatment. Br Med Bull, 2011; 100: 59-72
70. Stone KD, Prussin C: Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy, 2008; 38(12): 1858-65
71. Kibsgaard L, Skjold T, Deleuran M et al: Omalizumab Induced Remission of Idiopathic Anaphylaxis in a Patient Suffering from Indolent Systemic Mastocytosis. Acta Derm Venereol, 2014; 94(3): 363-64
72. Foster B, Foroughi S, Yin Y, Prussin C: Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders. Clin Mol Allergy, 2011; 9(1): 7
73. Bains SN, Hsieh FH: Current approaches to the diagnosis and treatment of systemic mastocytosis. Ann Allergy Asthma Immunol, 2010; 104(1): 1-10; quiz 10-12, 41
74. Ozdemir D, Dagdelen S, Erbas T: Systemic mastocytosis. Am J Med Sci, 2011; 342(5): 409-15
75. Söderholm JD: Mast cells and mastocytosis. Dig Dis, 2009; 27(Suppl.1): 129-36
76. Haenisch B, Nöthen MM, Molderings GJ: Systemic mast cell activation disease: the role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology, 2012; 137(3): 197-205
77. Horny HP: Mastocytosis: an unusual clonal disorder of bone marrow-derived hematopoietic progenitor cells. Am J Clin Pathol, 2009; 132(3): 438-47
78. Paraskevopoulos G, Sifnaios E, Christodoulopoulos K et al: Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol, 2013; 45(2): 52-55
79. Molderings GJ, Raithel M, Kratz F et al: Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med, 2011; 50(6): 611-15
80. Metz M, Ohanyan T, Church MK Maurer M: Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. J Dermatol Sci, 2014; 73(1): 57-62
81. Zuberbier T, Asero R, Bindslev-Jensen C et al: EAACI/GA(2)LEN/EDF/WAO guideline: management of urticarial. Allergy, 2009; 64(10): 1427-43
82. Gevaert P, Calus L, Van Zele T: Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol, 2013; 131: 110-16
83. Scadding GK, Gray P, Belvisi MG et al: High levels of nitric oxide synthase activity are associated with nasal polyp tissue from aspirin-sensitive asthmatics. Acta Otolaryngol, 2002; 122: 302-5
84. Iyengar SR, Hoyte EG, Loza A et al: Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebocontrolled clinical trial. Int Arch Allergy Immunol, 2013; 162(1): 89-93
85. Yalcin AD, Cilli A, Straus L: Omalizumab (Anti-IgE) Therapy Increases Blood Glucose Levels in Severe Persistent Allergic Asthma Patients with Diabetes Mellutus: 18 Months follow-up. Clin Lab, 2014; 60 DOI: 10.7754/Clin. Lab.2013.130302
86. Eisner MD, Zazzali JL, Miller MK et al: Longitudinal changes in asthma control with omalizumab: 2-year interim data from the EXCELS Study. J Asthma, 2012; 49(6): 642-48
87. Long AA, Fish JE, Rahmaoui A et al: Baseline characteristics of patients enrolled in EXCELS: a cohort study. Ann Allergy Asthma Immunol, 2009; 103(3): 212-19
88. Ali AK, Hartzema AG: Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. J Asthma Allergy, 2012; 5: 1-9
89. Barnes PJ: New drugs for asthma. Semin Respir Crit Care Med, 2012; 33(6): 685-94
90. Townley RG, Agrawal S, Sapkota K: Omalizumab for pediatric asthma. Expert Opin Biolog Ther, 2010; 10(11): 1595-608
91. Bousquet J, Mantzouranis E, Cruz AA et al: Uniform definition of asthma severity, control, andexacerbations: document presented for the World Health Organization Consultationon Severe Asthma. J Allergy Clin Immunol, 2010; 126: 926-38
92. Morishima T, Ikai H, Imanaka Y: Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and theValue of Responder Prediction Methods Based on a Multinational Trial. Value in Health Regional Issues, 2013; 2: 29-36
93. Lim S, Jatakanon A, John M et al: Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med, 1999; 159(1): 22-30
94. Bişgin A, Kargı A, Yalcin AD et al: Increased sTRAIL levels were correlated with patient survival in BevacizumAb treated metastatic colon cancer patients. BMC Cancer, 2012; 12: 58
95. Yalcin AD, Kargi A, Gumuslu S et al: Blood eosinophil and platelet levels, proteomics patterns of trail and CXCL8 correlated with survival in bevacizumab treated metastatic colon cancers. Clin lab. Clin Lab, 2014; 60 DOI: 10.7754/Clin.Lab.2013.130425
96. Celik B, Yalcin AD, Bisgin A et al: Level of TNF-related apoptosis-inducingligand and CXCL8 correlated with 2-[18F]Fluoro-2-deoxy-D-glucose uptake in anti-VEGF treated colon cancers. 2013; 19: 875-82
97. Kargi A, Yalcin AD, Erin N et al: IL8 and serum soluble TRAIL levels following anti-VEGF monoclonal antibody treatment in patients with metastatic colon cancer. Clin Lab, 2012; 58(9-10): 1103-7